Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 10, 2005, Pages 561-568

  Schulz, Hans Ulrich ^a   Schürer, Michael ^a   Bässler, Dagmar ^b   Weiser, Dieter ^b  

^a LAFAA Laboratory for Contract Research in Clinical Pharmacology and Biopharmaceutical Analytics GmbH   (Germany)

^b Steigerwald Arzneimittelwerk   (Germany)

Author keywords

Antidepressant; Flavonoids; Hyperforin; Hypericin; Hypericum perforatum; Laif 900; Pharmacokinetics; Pseudohypericin; STW 3 VI

Indexed keywords

AGLYCONE; ANTIDEPRESSANT AGENT; FLAVONOID; GLYCOSIDE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; ISORHAMNETIN; LAIF; NARINGENIN; PSEUDOHYPERICIN; QUERCETIN; STW 3 VI; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERICUM PERFORATUM; MALE; MEAN RESIDENCE TIME; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; STEADY STATE; TABLET; VOLUNTEER;

EID: 27544504385     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296905     Document Type: Article

References (19)

1. nd ed., Thieme, Stuttgart (2003)
2. Linde, K., Mulrow, C. D., Berner, M. et al., St. John's Wort for depression. The Cochrane Database of Systematic Reviews 2005, Issue 3 (2005)
3. Roby, C. A., Anderson, G. D., Kantor E. et al., St. John's wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther. 67, 451 (2000)
4. Wang, Z., Gorski, J. C., Hamman, M. A. et al., The effects of St John's wort (Hypericum perforatum) on human cytochrom P450 activity. Clin. Pharmacol. Ther. 70, 317 (2001)
5. St. John's Wort - Hyperici herba. European Pharmacopoeia, Council of Europe
6. Butterweck, V., Nahrstedt, A., Evans, J. et al., In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology 162, 193 (2002)
7. Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M. et al., Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 63, 499 (1998)
8. Butterweck, V., Jürgenliemk, G., Nahrstedt, A. et al., Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med. 66, 3 (2000)
9. Brockmöller, J., Reum, T., Bauer, S. et al., Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30 (Suppl.), 94 (1997)
10. Kerb, R., Brockmöller, J., Staffeldt, B. et al., Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob. Agents Chemother. 40, 2087 (1996)
11. Staffeldt, B., Kerb, R., Brockmöller, J. et al., Pharmakokinetik von Hypericin und Pseudohypericin nach oraler Einnahme des Johanniskraut-Extraktes LI 160 bei gesunden Probanden (Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers). Nervenheilkunde 12, 331 (1993)
12. 14C]- labelled hypericin and pseudohypericin from Hypericum perforatum and serum kinetics for hypericin in Man. Planta Med. 57 (Suppl2), A61 (1991)
13. Weiser, D., Pharmakokinetik von Hypericin nach oraler Einnahme des Johanniskraut-Extraktes LI 160. Nervenheilkunde 10, 318 (1991)
14. Schulz, H.-U., Schürer, M., Bässler, D. et al., Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneim.-Forsch./Drug Res. 55, 15 (2005)
15. Biber, A., Fischer, H., Römer, A. et al., Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31, 36 (1998)
16. Graefe, E. U., Derendorf, H., Veit, M., Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther. 37, 219 (1999)
17. Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation. FDA, CDER, CVM, Rockville, MD, USA (2001)
18. Erlund, I., Kosonen, T., Alfthan, G. et al., Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur. J. Clin. Pharmacol. 56, 545 (2000)
19. Graefe, E. U., Wittig, J., Mueller, S. et al., Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 41, 492 (2001)